MDGSW (Medigus) Current Deferred Taxes Liabilities: $0.00 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDGSW Medigus Ltd MDGSW
12 GF Score
Price $0.02
! 6 Warning Signs
View Full Analysis

What is Medigus Current Deferred Taxes Liabilities?

Medigus MDGSW 12 Current Deferred Taxes Liabilities is $0.00 Mil as of Dec. 2024. GuruFocus rates MDGSW with a GF Score™ of 12/100. The stock has 6 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Medigus's current deferred tax liabilities for the quarter that ended in Dec. 2024 was $0.00 Mil.

Medigus Current Deferred Taxes Liabilities Related Terms

Medigus Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Medigus's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigus Current Deferred Taxes Liabilities Chart

Medigus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medigus Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MDGSW
12GF Score
Medigus Ltd MDGSW
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of $0.00 Mil mean?
Medigus (MDGSW) has a Current Deferred Taxes Liabilities of $0.00 Mil as of Dec. 2024. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Medigus and its competitors.
Is Medigus' Current Deferred Taxes Liabilities too high?
Medigus' current Current Deferred Taxes Liabilities is $0.00 Mil. Overall, Medigus has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigus' Current Deferred Taxes Liabilities compare to RMSL and HSDT?
Medigus' Current Deferred Taxes Liabilities of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Medical Devices & Instruments company?
A good Current Deferred Taxes Liabilities depends on the Medical Devices & Instruments industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Medigus and its competitors. Medigus's current Current Deferred Taxes Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigus stock overvalued right now?
Medigus (MDGSW) has a current Current Deferred Taxes Liabilities of $0.00 Mil. The current Current Deferred Taxes Liabilities is $0.00 Mil. Medigus' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Medigus (MDGSW), the current Current Deferred Taxes Liabilities is $0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigus Business Description

Address 10 Hanechoshet Street, 4th Floor, Tel Aviv, ISR, 6971072
Xylo Technologies Ltd is an Israel-based medical device company. The company is engaged in the development, manufacturing, and marketing of direct vision systems for minimally invasive medical procedures and safety systems for drones and the electric vehicle (EV) sector. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incision-less treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company operates in four segments are: Corporate, Online advertising & internet traffic routing, Online event management, real-estate and electronics. The company's geographical segments include USA, Europe, Great Britain, Israel, Canada, Asia and others.
12GF Score

Get the complete analysis for MDGSW

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price